<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 14, 1999
------------------
Cephalon, Inc.
--------------------------------------------------------------------
(Exact name of registrant specified in Charter)
Delaware 0-19119 23-2484489
--------------------------------------------------------------------
(State or other (Commission (IRS Employee
jurisdiction of File Number) Identification No.)
incorporation)
145 Brandywine Parkway
West Chester, PA 19380
--------------------------------------------------------------------
(Address of principal executive offices) Zip Code
Registrant's telephone, including area code: 610-344-0200
--------------------------------------------------------------------
(Former name and former address, if changed since last report)
<PAGE>
Item 5. Other Events
------------
The Company received in November 1999, and is responding to, a federal
grand jury subpoena in connection with an investigation under the supervision of
the Office of Consumer Litigation of the U.S. Department of Justice. The grand
jury also issued subpoenas to certain former and current employees of the
Company. The Company believes that the investigation relates to the release
during the period 1994-96 of some lots of Myotrophin used in clinical trials and
related reports filed with the U.S. Food and Drug Administration. The Company
has not been identified by the Department of Justice as being a target of the
investigation and is cooperating with the inquiry. The Company cannot predict
the outcome of the investigation.
<PAGE>
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CEPHALON, INC.
Date: December 14, 1999 By: /s/ J. Kevin Buchi
--------------------------------------
J. Kevin Buchi
Senior Vice President, Chief Financial Officer
